Subtopic Deep Dive
Estrogen Receptor Alpha Signaling
Research Guide
What is Estrogen Receptor Alpha Signaling?
Estrogen Receptor Alpha (ERα) signaling encompasses the genomic and non-genomic mechanisms by which ERα mediates estrogen effects on gene transcription and rapid cellular responses.
ERα signaling involves ligand binding that induces conformational changes, co-regulator recruitment, and transcriptional activation or repression (Glass and Rosenfeld, 2000, 2222 citations). Non-genomic actions include rapid ERK1/2 activation via GPR30 and EGFR transactivation (Filardo et al., 2000, 1310 citations). Over 10 key papers document SERM mechanisms like tamoxifen and pure antiestrogens.
Why It Matters
ERα signaling research underpins breast cancer therapies, with tamoxifen standard for hormone-dependent cases and letrozole extending benefits post-tamoxifen (Goss et al., 2003, 1821 citations; Goss et al., 2005, 1113 citations). Exemestane after tamoxifen improves disease-free survival (Coombes et al., 2004, 1762 citations). Raloxifene reduces invasive breast cancer risk in postmenopausal women (Barrett-Connor et al., 2006, 1035 citations), while pure antiestrogens like ICI 164,384 offer clinical potential (Wakeling et al., 1991, 1106 citations). Letrozole outperforms tamoxifen in ErbB-positive tumors (Ellis et al., 2001, 1062 citations).
Key Research Challenges
Co-regulator Exchange Dynamics
ERα recruits distinct coactivators or corepressors based on ligand-induced conformations, complicating SERM design (Glass and Rosenfeld, 2000). Variability in co-regulator interactions across cell types hinders predictive modeling. Over 2000 citations highlight unresolved tissue-specific mechanisms.
Genomic vs Non-Genomic Balance
Rapid ERK activation via GPR30 occurs independently of classical ERα, blurring signaling pathways (Filardo et al., 2000, 1310 citations). Distinguishing contributions to therapeutic resistance remains difficult. Clinical trials show inconsistent responses tied to these pathways.
SERM Resistance Mechanisms
Tamoxifen resistance in ErbB-positive cancers requires alternative inhibitors like letrozole (Ellis et al., 2001, 1062 citations). Long-term therapy outcomes vary, as seen in extended adjuvant trials (Goss et al., 2005). Predicting patient-specific responses lacks robust biomarkers.
Essential Papers
The coregulator exchange in transcriptional functions of nuclear receptors
Christopher K. Glass, Michael G. Rosenfeld · 2000 · Genes & Development · 2.2K citations
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Paul E. Goss, James N. Ingle, Silvana Martino et al. · 2003 · New England Journal of Medicine · 1.8K citations
In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy--but not tamoxifen therapy of longer duration--prolongs disease-free and overall survival. The aromatase inhibitor ...
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
R. Charles Coombes, Emma Hall, Lorna J. Gibson et al. · 2004 · New England Journal of Medicine · 1.8K citations
Exemestane therapy after two to three years of tamoxifen therapy significantly improved disease-free survival as compared with the standard five years of tamoxifen treatment.
The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed
Mark R. Haussler, G. Kerr Whitfield, Carol A. Haussler et al. · 1998 · Journal of Bone and Mineral Research · 1.4K citations
In the decade since the vitamin D receptor (VDR) was cloned1 and recognized as a member of the superfamily of nuclear receptors that regulate gene expression in a ligand-dependent manner,2, 3 the c...
Estrogen-Induced Activation of Erk-1 and Erk-2 Requires the G Protein-Coupled Receptor Homolog, GPR30, and Occurs via Trans-Activation of the Epidermal Growth Factor Receptor through Release of HB-EGF
Edward J. Filardo, Jeffrey A. Quinn, Kirby I. Bland et al. · 2000 · Molecular Endocrinology · 1.3K citations
Estrogen rapidly activates the mitogen-activated protein kinases, Erk-1 and Erk-2, via an as yet unknown mechanism. Here, evidence is provided that estrogen-induced Erk-1/-2 activation occurs indep...
Estrogen receptors and human disease
Bonnie J. Deroo · 2006 · Journal of Clinical Investigation · 1.3K citations
Estrogens influence many physiological processes in mammals, including but not limited to reproduction, cardiovascular health, bone integrity, cognition, and behavior. Given this widespread role fo...
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
Paul E. Goss, James N. Ingle, Silvana Martino et al. · 2005 · JNCI Journal of the National Cancer Institute · 1.1K citations
Letrozole after tamoxifen is well-tolerated and improves both disease-free and distant disease-free survival but not overall survival, except in node-positive patients.
Reading Guide
Foundational Papers
Start with Glass and Rosenfeld (2000, 2222 citations) for coregulator exchange fundamentals, then Filardo et al. (2000, 1310 citations) for non-genomic GPR30 mechanisms, as they establish ERα signaling paradigms cited in all SERM trials.
Recent Advances
Study Goss et al. (2005, 1113 citations) for extended letrozole adjuvant therapy updates; Barrett-Connor et al. (2006, 1035 citations) for raloxifene outcomes; Deroo (2006, 1294 citations) links ER to human disease.
Core Methods
Randomized trials assess SERM efficacy (Goss et al., 2003; Coombes et al., 2004); molecular assays detect ERK activation and HB-EGF release (Filardo et al., 2000); pure antiestrogen synthesis evaluates conformations (Wakeling et al., 1991).
How PapersFlow Helps You Research Estrogen Receptor Alpha Signaling
Discover & Search
Research Agent uses searchPapers and citationGraph to map ERα coregulator networks from Glass and Rosenfeld (2000), revealing 2222 citing papers on co-regulator exchange. exaSearch uncovers SERM trials like Goss et al. (2003); findSimilarPapers links non-genomic GPR30 work (Filardo et al., 2000) to recent resistance studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract tamoxifen-letrozole trial data from Goss et al. (2003), then verifyResponse with CoVe checks survival metrics against abstracts. runPythonAnalysis with pandas computes disease-free survival differences across Coombes et al. (2004) and Goss et al. (2005); GRADE grading scores evidence strength for SERM efficacy.
Synthesize & Write
Synthesis Agent detects gaps in non-genomic ERα signaling beyond GPR30 (Filardo et al., 2000), flagging contradictions with classical pathways. Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing Wakeling et al. (1991), with latexCompile generating figures and exportMermaid for signaling pathway diagrams.
Use Cases
"Compare survival stats from letrozole vs tamoxifen trials in ER+ breast cancer"
Research Agent → searchPapers('Goss 2003 letrozole') → Analysis Agent → readPaperContent + runPythonAnalysis(pandas on survival data) → CSV export of hazard ratios and p-values.
"Draft LaTeX review on ERα non-genomic signaling with citations"
Synthesis Agent → gap detection on Filardo 2000 → Writing Agent → latexEditText('review text') → latexSyncCitations('Glass 2000, Filardo 2000') → latexCompile → PDF with pathway diagram.
"Find code for ERα signaling simulations from related papers"
Research Agent → citationGraph('Glass 2000') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for co-regulator binding models.
Automated Workflows
Deep Research workflow scans 50+ ERα papers via searchPapers on SERMs, producing structured reports with GRADE-scored trial evidence from Goss et al. (2003) and Coombes et al. (2004). DeepScan applies 7-step CoVe verification to non-genomic claims (Filardo et al., 2000), checkpointing signaling mechanisms. Theorizer generates hypotheses on co-regulator exchanges from Glass and Rosenfeld (2000) abstracts.
Frequently Asked Questions
What defines ERα signaling?
ERα signaling includes genomic transcription via co-regulator exchange (Glass and Rosenfeld, 2000) and non-genomic ERK activation via GPR30 (Filardo et al., 2000).
What are key methods in ERα research?
Clinical trials test SERMs like tamoxifen and letrozole (Goss et al., 2003; Coombes et al., 2004); biochemical assays reveal GPR30-EGFR transactivation (Filardo et al., 2000).
What are top papers on ERα signaling?
Glass and Rosenfeld (2000, 2222 citations) on coregulators; Filardo et al. (2000, 1310 citations) on non-genomic paths; Goss et al. (2003, 1821 citations) on letrozole therapy.
What open problems exist?
SERM resistance in ErbB+ tumors (Ellis et al., 2001); tissue-specific co-regulator dynamics (Glass and Rosenfeld, 2000); integrating genomic/non-genomic contributions.
Research Estrogen and related hormone effects with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Estrogen Receptor Alpha Signaling with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.